Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemonoxacin vs Levofloxacin in CAP
NCT02205112Phase 3Completed
- Sponsor
- TaiGen Biotechnology Co., Ltd.
- Start
- Jun 2014
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of nemonoxacin in community acquired pneumonia (CAP) (2 arms), sponsored by TaiGen Biotechnology Co., Ltd. Primary endpoint: Per subject clinical cure rate. Started Jun 2014; status: completed.
02
Drugs
nemonoxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT02205112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02205112.